All Articles

As data breaches soar, a top marketing mind from LifeLock joins AI startup PrivacyHawk. Can they redefine personal data protection for millions?

Evolve's acquisition of 1,000 properties from Casago signals a major industry shift toward specialized, tech-driven vacation rental management models.

Hall Chadwick's $207M IPO signals a renewed appetite for SPACs. For capital-hungry AI health tech firms, this could be a new path to the public market.

Sabio's revenue fell in a non-political year, but surging programmatic and international sales signal a strategic shift. Is it enough for a 2026 rebound?

A C$30M financing, led by Pan American Silver, accelerates Galleon Gold's West Cache project and signals a strategic shift in the Timmins gold camp.

Rocket Lab's record-setting 19th launch of 2025 will carry a JAXA tech-demo satellite, a mission highlighting market leadership and US-Japan space diplomacy.

Real estate firm Montium taps a cross-sector HR leader to scale its $1B portfolio. This isn't just an HR hire; it's a blueprint for growth.

AIoT leader Tuya returns to profitability, proving operational discipline and a robust developer ecosystem can overcome global trade uncertainties.

Beyond the numbers, United Rentals' recent debt refinancing is a strategic move to fortify its market leadership and fund future innovation.

Marten Transport's 62nd straight dividend signals resilience. But what does its performance in cold chain logistics tell us about broader economic health?

CoStar Group's Homes.com is challenging the portal giants with a pro-agent model and new tech. Can its audacious strategy deliver resilient returns?

New survival data for Inluriyo, precision insights for Verzenio, and a next-gen drug signal Lilly's aggressive strategy to dominate HR+ breast cancer.

Specialty materials firm Mativ appoints a culture and transformation expert to its board, signaling a strategic pivot to human capital as a key driver of post-merger growth.

Bed Bath & Beyond's acquisition of The Brand House Collective is a bold play for profitability, aiming for $20M in savings and a new omnichannel strategy.

A routine stock grant at Forte Biosciences reveals a fierce talent war and offers savvy investors a rare glimpse into the high-stakes world of biotech innovation.

With a new lung cancer drug approved and an obesity treatment in the wings, Amgen's investor talk is a key bellwether for biotech's future in Canada.

With a major non-dilutive financing deal, Nanobiotix de-risks its pipeline and expands its nanotechnology platform beyond its lead cancer drug.

Materials giant Westlake hits its 2030 emissions target six years early, raising the bar and signaling a strategic shift for industrial supply chains.

We vet the season's hottest gadgets, from smart vacuums to flip phones, and uncover the sophisticated marketing machine that puts them on your TV screen.

Beyond the stock ticker, Nuvalent's massive capital raise reveals a deeper story about investor confidence, patient hope, and the future of cancer therapy.